1-(4-(6-chloro-2-isopropyl-1-oxoisoindolin-5-yl)benzyl)-3-methylimidazolidine-2,4-dione | 1295301-91-5

• 分子结构分类: 有机化合物
• 英文名称: 1-(4-(6-chloro-2-isopropyl-1-oxoisoindolin-5-yl)benzyl)-3-methylimidazolidine-2,4-dione
• 英文别名: 1-[[4-(6-chloro-1-oxo-2-propan-2-yl-3H-isoindol-5-yl)phenyl]methyl]-3-methylimidazolidine-2,4-dione
• CAS: 1295301-91-5
• 化学式: C₂₂H₂₂ClN₃O₃
• 分子量: 411.888
• InChiKey: LHIAYXKOVVBJRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  60.9
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• HETEROCYCLIC DERIVATIVES
  申请人：Adam Julia

  公开号：US20120220622A1

  公开（公告）日：2012-08-30

  The present invention relates to a heterocyclic derivative of formula (I) wherein the variables are as defined in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to pharmaceutical compositions comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of disorders mediated by glutamate dysfunction, such as schizophrenia and generalised anxiety disorder.

  本发明涉及一种公式(I)的杂环衍生物，其中变量如规范中所定义，或其药学上可接受的盐或溶剂。本发明还涉及包含所述杂环衍生物的制药组合物，以及它们在治疗中的使用，例如在治疗或预防由谷氨酸功能障碍介导的疾病，例如精神分裂症和广泛性焦虑症。
• US8507521B2
  申请人：——

  公开号：US8507521B2

  公开（公告）日：2013-08-13
• [EN] HETEROCYCLIC DERIVATIVES<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES
  申请人：ORGANON NV

  公开号：WO2011051490A2

  公开（公告）日：2011-05-05

  The present invention relates to a heterocyclic derivative of formula (I) wherein the variables are as defined in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to pharmaceutical compositions comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of disorders mediated by glutamate dysfunction, such as schizophrenia and generalised anxiety disorder.